These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32215059)

  • 1. Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release.
    Liu X; Wen J; Yi H; Hou X; Yin Y; Ye G; Wu X; Jiang X
    Ther Adv Med Oncol; 2020; 12():1758835920910347. PubMed ID: 32215059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W; Liu Y; Hu Y; Gao J
    Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
    Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
    J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro.
    Huang Y; Zeng J; Liu T; Xu Q; Song X; Zeng J
    Cancer Manag Res; 2020; 12():3247-3255. PubMed ID: 32440221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFRvIII-specific CAR-T cells produced by piggyBac transposon exhibit efficient growth suppression against hepatocellular carcinoma.
    Ma Y; Chen Y; Yan L; Cao HX; Han SY; Cui JJ; Wen JG; Zheng Y
    Int J Med Sci; 2020; 17(10):1406-1414. PubMed ID: 32624697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.
    Li K; Qian S; Huang M; Chen M; Peng L; Liu J; Xu W; Xu J
    Am J Transl Res; 2021; 13(1):156-167. PubMed ID: 33527015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase signaling-independent MET-targeting with CAR-T cells.
    Qin A; Qin Y; Lee J; Musket A; Ying M; Krenciute G; Marincola FM; Yao ZQ; Musich PR; Xie Q
    J Transl Med; 2023 Oct; 21(1):682. PubMed ID: 37779207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.
    Guo X; Jiang H; Shi B; Zhou M; Zhang H; Shi Z; Du G; Luo H; Wu X; Wang Y; Sun R; Li Z
    Front Pharmacol; 2018; 9():1118. PubMed ID: 30327605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma.
    Jiang Z; Jiang X; Chen S; Lai Y; Wei X; Li B; Lin S; Wang S; Wu Q; Liang Q; Liu Q; Peng M; Yu F; Weng J; Du X; Pei D; Liu P; Yao Y; Xue P; Li P
    Front Immunol; 2016; 7():690. PubMed ID: 28123387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma.
    Wang P; Qin W; Liu T; Jiang D; Cui L; Liu X; Fang Y; Tang X; Jin H; Qian Q
    Immunobiology; 2020 Jan; 225(1):151850. PubMed ID: 31522780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
    Pang N; Shi J; Qin L; Chen A; Tang Y; Yang H; Huang Y; Wu Q; Li X; He B; Li T; Liang B; Zhang J; Cao B; Liu M; Feng Y; Ye X; Chen X; Wang L; Tian Y; Li H; Li J; Hu H; He J; Hu Y; Zhi C; Tang Z; Gong Y; Xu F; Xu L; Fan W; Zhao M; Chen D; Lian H; Yang L; Li P; Zhang Z
    J Hematol Oncol; 2021 Jul; 14(1):118. PubMed ID: 34325726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma.
    Zhai Y; He K; Huang L; Shang X; Wang G; Yuan G; Han ZG
    Liver Int; 2022 Nov; 42(11):2524-2537. PubMed ID: 36002393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.
    Zhou L; Li Y; Zheng D; Zheng Y; Cui Y; Qin L; Tang Z; Peng D; Wu Q; Long Y; Yao Y; Wong N; Lau J; Li P
    Mol Ther Oncol; 2024 Jun; 32(2):200817. PubMed ID: 38882528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
    Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
    Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.
    Caraballo Galva LD; Jiang X; Hussein MS; Zhang H; Mao R; Brody P; Peng Y; He AR; Kehinde-Ige M; Sadek R; Qiu X; Shi H; He Y
    Hepatology; 2022 Aug; 76(2):330-344. PubMed ID: 34897774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells
    Huang X; Guo J; Li T; Jia L; Tang X; Zhu J; Tang Q; Feng Z
    J Biomed Res; 2021 Dec; 36(1):10-21. PubMed ID: 35403606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
    Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
    J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.